GlassScriptPhysician profile
Sarah Hunt
NPI 1104552066
$4,156.00
in general payments reported to CMS, 2019-2025
21 companies · $78.99 in 2025
The $78.99 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $520 · 2023: $2,300 · 2024: $1,257 · 2025: $78.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,635.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $796.54 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $588.26 | 2022-2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $434.70 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $387.93 | 2022-2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $363.22 | 2022-2023 | Austedo, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $288.34 | 2022-2024 | Spravato |
| Abbvie INC. | $257.83 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $151.28 | 2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $118.27 | 2024 | Cobenfy |
| Lundbeck LLC | $105.77 | 2022-2025 | Rexulti, Brintellix |
| Alkermes, INC. | $102.85 | 2022-2025 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.52 | 2022-2023 | Trintellix |
| Corium, LLC | $78.80 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $78.21 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $59.52 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $48.22 | 2022 | |
| Atricure, INC. | $45.15 | 2023-2024 | |
| Indivior INC. | $25.90 | 2023 | Sublocade |
| Bausch Health US, LLC | $22.67 | 2023 | Aplenzin |
| Almatica Pharma LLC | $17.02 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.